Literature DB >> 2253654

Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.

J B Lecaillon1, J P Dubois, H Coppens, T Darragon, G Reumond, N Pozet, J Traeger, G Lambrey.   

Abstract

The pharmacokinetics of oxiracetam in patients with renal impairment were investigated after administration of a 800 mg single oral dose of oxiracetam. The renal insufficiency was estimated on the basis of the creatinine clearance (CLcr) which ranged from 9 to 95 ml/min among the 20 patients. In plasma, the terminal elimination half-life (T1/2) ranged from 10.6 to 68.1 h, the highest T1/2 corresponding to the patients with a high degree of renal impairment. In urine, the amounts of oxiracetam excreted during the 48 h postdosing represented 8.3 to 82.6% of the dose. They were lower in patients with a high degree of renal impairment. The correlations between the total clearance of oxiracetam, the renal clearance, the terminal apparent elimination rate constant in plasma, and CLcr were estimated by linear regression analysis. The correlation coefficients were 0.916, 0.985 and 0.803 respectively. The apparent volume of distribution of the central compartment V(1) and the total volume of distribution at the steady-state V(SS) were not dependent on the degree of renal impairment. The mean values +/- SD were 25.9 +/- 13.0 litres and 48.3 +/- 21.5 litres respectively. Oxiracetam concentrations in plasma of patients were estimated for repeated administration of 800 mg of oxiracetam.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253654     DOI: 10.1007/BF03190209

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  6 in total

1.  Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects.

Authors:  J B Lecaillon; J P Dubois; H Coppens; T Darragon; W Theobald; G Reumond; H Beck
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

2.  Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.

Authors:  C Villardita; J Parini; S Grioli; M Quattropani; C Lomeo; U Scapagnini
Journal:  J Neural Transm Suppl       Date:  1987

3.  An incremental method for the study of the absorption of drugs whose kinetics are described by a two-compartment model: estimation of the microscopic rate constants.

Authors:  A Gerardin; D Wantiez; A Jaouen
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

4.  Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.

Authors:  E Perucca; A Albrici; G Gatti; R Spalluto; M Visconti; A Crema
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

5.  Determination of oxiracetam in plasma and urine by column-switching high-performance liquid chromatography.

Authors:  J B Lecaillon; C Souppart; F Le Duigou; J P Dubois
Journal:  J Chromatogr       Date:  1989-12-29

6.  Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly.

Authors:  E Perucca; J Parini; A Albrici; M Visconti; E Ferrero
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

  6 in total
  1 in total

1.  Absorption and disposition of 14C-labelled oxiracetam in rat, dog and man.

Authors:  H P Gschwind; H Schütz; N Wigger; P Bentley
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.